Genentech seeks FDA approval for Lunsumio VELO plus Polivy in relapsed/refractory LBCL
- FDA accepted Genentech’s sBLA for subcutaneous Lunsumio VELO (mosunetuzumab‑axgb) combined with Polivy (polatuzumab vedotin) for adult relapsed/refractory LBCL.
- Regulatory review based on Phase III SUNMO: 59% reduction in risk of progression or death (HR 0.41; 95% CI 0.28–0.61; p<0.0001) with median PFS 11.5 vs 3.8 months.
- Median follow‑up in SUNMO was 23.2 months; updated ASCO and EHA presentations showed sustained PFS benefit, especially in the second‑line setting, with no new safety signals.
- Safety: cytokine release syndrome occurred in ~25% of patients with <5% experiencing Grade 2–3 events; overall safety consistent with known profiles of the medicines.
Regulatory filing and timeline
The U.S. Food and Drug Administration has accepted Genentech’s supplemental Biologics License Application for subcutaneous Lunsumio VELO (mosunetuzumab‑axgb) in combination with Polivy (polatuzumab vedotin) to treat adults with relapsed or refractory large B‑cell lymphoma, including DLBCL, after at least one prior systemic therapy. The FDA is expected to decide by February 9, 2027.
Key SUNMO efficacy data
The sBLA is supported by Phase III SUNMO results with a median follow‑up of 23.2 months. Lunsumio VELO plus Polivy reduced the risk of disease progression or death by 59% versus R‑GemOx (HR 0.41; 95% CI 0.28–0.61; p<0.0001) and produced a median PFS of 11.5 months versus 3.8 months for R‑GemOx.
Safety profile
The combination’s safety was consistent with known profiles of each agent. Cytokine release syndrome occurred in about one in four patients, with fewer than 5% experiencing Grade 2–3 CRS events. Updated data presented at ASCO and EHA reported no new safety signals.
Clinical context and access implications
The regimen is described as chemotherapy‑free and outpatient‑ready; if approved, the subcutaneous option could facilitate treatment in community settings for patients who are ineligible for transplant or face logistical barriers to care.
Source: Genentech
